Treatment of Pericardial Effusion

Immediate Management

• Pericardiocentesis is mandatory for cardiac tamponade regardless of etiology, and this represents a Class I indication that takes absolute priority over all other considerations, according to the European Society of Cardiology 1, 2
• Echocardiographic or fluoroscopic guidance should be used during pericardiocentesis to minimize complications including myocardial laceration, pneumothorax, and mortality, as recommended by the European Society of Cardiology 1, 2
• Patients with dehydration and hypovolemia may temporarily improve with intravenous fluids while preparing for drainage, as suggested by the European Society of Cardiology 3

Medical Treatment Algorithm for Non-Tamponade Effusions

• Treatment duration for non-tamponade effusions should be at least 3 months with gradual tapering, according to the European Society of Cardiology 3
• Corticosteroids should be tapered over a three-month period, as recommended by the European Society of Cardiology 3
• Patients should be on a steroid-free regimen for several weeks before any surgical intervention, according to the European Society of Cardiology 3

Etiology-Specific Management

• Systemic antineoplastic treatment is the baseline therapy for confirmed malignant effusions, with pericardial drainage recommended in all patients with large effusions due to high recurrence rates, as suggested by the European Society of Cardiology 1, 2
• Intrapericardial instillation of cytostatic/sclerosing agents should be considered to prevent recurrences, according to the European Society of Cardiology 1, 2
• Cisplatin is most effective for lung cancer pericardial involvement, as recommended by the European Society of Cardiology 1, 2
• Thiotepa is more effective for breast cancer pericardial metastases, according to the European Society of Cardiology 1, 2
• Tetracyclines as sclerosing agents control malignant effusion in 85% of cases, but side effects are frequent, as reported by the European Society of Cardiology 1, 2
• Radiation therapy is very effective (93%) for radiosensitive tumors such as lymphomas and leukemias, as suggested by the European Society of Cardiology 1, 2

Surgical Options for Recurrent or Refractory Effusions

• Percutaneous balloon pericardiotomy is effective (90-97%) and safe for large malignant effusions with recurrent tamponade, creating pleuropericardial communication for fluid drainage, according to the European Society of Cardiology 1, 2
• Pericardial window creation via left minithoracotomy is safe and effective for malignant cardiac tamponade, as recommended by the European Society of Cardiology 1, 2
• Pericardiectomy is indicated only for frequent and highly symptomatic recurrences resistant to medical treatment, pericardial constriction, or complications of previous procedures, according to the European Society of Cardiology 1, 2, 3
• Post-pericardiectomy recurrences can occur, possibly due to incomplete resection of the pericardium, as reported by the European Society of Cardiology 3

Indications for Pericardiocentesis Beyond Tamponade

• Cytological analyses of pericardial fluid are recommended for confirmation of malignant pericardial disease, according to the European Society of Cardiology 2
• Pericardial or epicardial biopsy should be considered when malignancy is suspected and cannot be confirmed by less invasive means, as suggested by the European Society of Cardiology 2

Treatment of Pericardial Effusion

Immediate Management Based on Hemodynamic Status

• The European Society of Cardiology recommends pericardiocentesis or cardiac surgery for cardiac tamponade regardless of etiology 4
• Pericardiocentesis or cardiac surgery is indicated for symptomatic moderate-to-large effusions unresponsive to medical therapy, according to the European Heart Journal 4
• Echocardiographic or fluoroscopic guidance should be used for pericardiocentesis to minimize complications, as suggested by the European Heart Journal 5

Medical Treatment Algorithm

• The European Society of Cardiology recommends first-line therapy with NSAIDs (aspirin 750-1000 mg three times daily or ibuprofen 600 mg three times daily) plus colchicine (0.5 mg once or twice daily) for effusions with associated inflammation/pericarditis 5, 6
• For post-myocardial infarction pericarditis, aspirin is the preferred NSAID over other NSAIDs, according to the European Society of Cardiology 6
• The European Society of Cardiology recommends second-line therapy with corticosteroids for patients with contraindications to or failure of first-line therapy 5, 6

Etiology-Specific Management

• The European Society of Cardiology recommends empiric anti-TB chemotherapy for exudative pericardial effusion after excluding other causes in endemic areas 4
• Standard anti-TB drugs for 6 months are required to prevent tuberculous pericardial constriction, according to the European Society of Cardiology 4, 5
• Systemic antineoplastic treatment is the baseline therapy for confirmed malignant effusions, as recommended by the European Society of Cardiology 4, 6
• Intrapericardial instillation of cytostatic/sclerosing agents should be considered to prevent recurrences, according to the European Society of Cardiology 7, 5, 6

Surgical Options for Recurrent or Refractory Effusions

• Percutaneous balloon pericardiotomy creates pleuropericardial communication and is effective (90-97%) for large malignant effusions with recurrent tamponade, as reported by the European Heart Journal 7
• Surgical pericardiotomy via left minithoracotomy is safe and effective for malignant cardiac tamponade, according to the European Heart Journal 7

Monitoring and Follow-Up Strategy

• Moderate idiopathic effusions require echocardiographic follow-up every 6 months, as recommended by the European Society of Cardiology 5, 6
• Large chronic effusions carry a 30-35% risk of progression to cardiac tamponade and require more vigilant monitoring every 3-6 months, according to the European Society of Cardiology 5, 6, 8

Critical Pitfalls to Avoid

• Anticoagulation should not be used in the setting of iatrogenic pericardial effusion, as it increases risk of tamponade, according to the European Heart Journal 9
• Corticosteroids should be reserved for second-line treatment due to higher recurrence rates, as recommended by the European Society of Cardiology 5, 6

Pericardial Drain Management Guidelines

Drain Duration and Removal Timing

• The American College of Cardiology recommends that the pericardial drain should be left in place for 3-5 days and continued until drainage falls below 25 mL per 24-hour period 10, 11
• Prolonged drainage is mandatory until the volume obtained by intermittent aspiration (every 4-6 hours) falls to less than 25 mL per day, as suggested by the European Heart Journal 11

Monitoring During Drainage

• The European Heart Journal recommends checking drain position in at least two angiographic projections before insertion, and monitoring output every 4-6 hours 11
• Echocardiographic or fluoroscopic guidance should be used during initial placement to minimize complications, including myocardial laceration and pneumothorax, as recommended by the European Heart Journal 11
• Drain fluid in less than 1-liter increments to avoid acute right ventricular dilatation, as suggested by the European Heart Journal 11

Indications for Surgical Intervention

• The American College of Cardiology suggests that if drainage output remains high (>25 mL/day) at 6-7 days post-pericardiocentesis, surgical pericardial window should be considered 10
• Surgical drainage is preferred over prolonged catheter drainage in traumatic hemopericardium and purulent pericarditis, as recommended by the European Heart Journal 11

Special Considerations by Etiology

• The American College of Cardiology recommends considering intrapericardial instillation of chemotherapeutic agents through the drain before removal for malignant effusions 10
• Cisplatin is most effective for lung cancer pericardial involvement (93% and 83% free of recurrence at 3 and 6 months respectively), as suggested by the American College of Cardiology 10

Critical Contraindications

• The European Heart Journal recommends never performing pericardiocentesis in aortic dissection with hemopericardium except for controlled drainage of very small amounts to temporarily maintain blood pressure at 90 mmHg as a bridge to definitive surgery 12
• Aortic dissection is a major contraindication to standard pericardiocentesis, as stated by the European Heart Journal 11
• Relative contraindications include uncorrected coagulopathy, anticoagulant therapy, thrombocytopenia <50,000/mm³, and small posterior or loculated effusions, as recommended by the European Heart Journal 11

Antibiotic Coverage for Pericardial Drains

Introduction to Antibiotic Use

• The European Society of Cardiology recommends against routine prophylactic antibiotics for pericardial drainage procedures or while drains remain in situ for non-infectious etiologies 13, 14

When Antibiotics Are Indicated

• The European Society of Cardiology suggests that aggressive intravenous antibiotic therapy must be initiated immediately and continued throughout the drainage period if purulent or bacterial pericarditis is suspected or confirmed 13, 14, 15
• For purulent pericarditis, empiric antibiotic regimens should include coverage for Staphylococcus, Streptococcus, Haemophilus, and gram-negatives, and should be started urgently before microbiological results are available 15

Specific Antibiotic Regimens

• The European Society of Cardiology recommends standard four-drug anti-TB therapy for 6 months when tuberculous pericarditis is confirmed or strongly suspected in endemic areas 13, 14
• Antifungal treatment is indicated for confirmed or suspected fungal pericarditis, particularly in immunocompromised patients, with options including fluconazole, ketoconazole, itraconazole, or amphotericin B formulations 16, 17

Diagnostic Considerations

• Urgent pericardiocentesis is both diagnostic and therapeutic when bacterial pericarditis is suspected, with key fluid characteristics mandating antibiotics including frankly purulent appearance, low pericardial:serum glucose ratio, and elevated white cell count with high neutrophils 15

Duration of Antibiotic Therapy

• The pericardial drain should remain in place for 3-5 days and until drainage falls below 25mL per 24-hour period, with antibiotics continued throughout the entire drainage period and typically for several weeks total 15

Timing of Repeat 2D Echocardiography After Pericardial Window for Malignant Pericardial Effusion

Immediate Post-Procedure Monitoring

• The American College of Cardiology recommends performing echocardiography immediately if signs of recurrent tamponade develop, including dyspnea, hypotension, tachycardia, pulsus paradoxus, or elevated jugular venous pressure, in patients who have undergone pericardial window for malignant pericardial effusion 18, 19, 20
• Clinical deterioration should prompt urgent imaging rather than waiting for scheduled follow-up, as cardiac tamponade requires emergency intervention in patients with a history of malignant pericardial effusion 18, 19

Routine Surveillance Strategy

• The European Society of Cardiology supports the idea that repeat 2D echocardiography should be performed if clinical symptoms develop or within 3-6 months for asymptomatic surveillance, with more frequent monitoring warranted in high-risk patients with lung adenocarcinoma or progressive disease despite chemotherapy 21

Clinical Context and Pitfalls

• The American College of Cardiology recommends against routine follow-up echocardiography in patients with terminal cancer where management would not be influenced by findings, taking into account the patient's overall prognosis and quality of life goals 22
• Any new symptoms mandate immediate echocardiography regardless of scheduled timing, as this may indicate recurrent tamponade or other complications in patients who have undergone pericardial window for malignant pericardial effusion 18, 19, 20

Pericardial Window: Indications, Limitations, and When to Prefer Pericardiectomy

Indications

• A pericardial window is recommended for patients with recurrent large pericardial effusions or cardiac tamponade when a full pericardiectomy carries excessive surgical risk or when the patient’s life expectancy is limited, especially in the setting of malignant pericardial disease. 23
• It is indicated when conservative therapy or repeated pericardiocentesis have failed to control the effusion. 23
• It is appropriate for high‑risk surgical candidates who cannot tolerate more extensive operations such as pericardiectomy. 23
• It serves a palliative purpose in patients with malignant pericardial involvement and reduced expected survival. 23

Limitations and Expected Outcomes

• The drainage communication created by a pericardial window may close over time, leading to recurrent effusions, particularly when the effusion becomes loculated. 23
• Overall recurrence rates range from 8 % to 10 %, with the video‑assisted thoracoscopic (VATS) approach providing superior long‑term control compared with subxiphoid techniques. 23
• When the window closes or effusions become loculated, additional interventions (e.g., repeat window creation or conversion to pericardiectomy) may be required. 23

Situations Favoring Pericardiectomy Over a Pericardial Window

• Constrictive pericarditis is the primary indication for a definitive pericardiectomy rather than a pericardial window. 23
• Patients experiencing frequent, highly symptomatic recurrences that are refractory to medical therapy may be better served by pericardiectomy. 23
• When complications arise from prior pericardial procedures, a pericardiectomy may be the preferred definitive treatment. 23

All statements are based on evidence reported in the European Heart Journal (2015) and reflect the cited source 23.

ESC Guideline Recommendations for Pericardial Effusion Management

Emergency Management of Cardiac Tamponade

• The European Society of Cardiology (ESC) advises that immediate pericardiocentesis or cardiac surgery must be performed without delay in any patient with cardiac tamponade, irrespective of the underlying cause (Class I, Level C) 24.
• Pericardiocentesis is absolutely contraindicated in patients with aortic dissection and hemopericardium; urgent surgical repair should be pursued instead (Class I, Level C) 24.

Malignant Pericardial Effusion

• Systemic antineoplastic therapy is the cornerstone of treatment and can prevent recurrence in up to 67 % of cases (Class IIa, Level B) 24, 25.
• Pericardial drainage is recommended for all patients with large malignant effusions (Class I indication) (Level C) 24, 25.
• Following drainage, intrapericardial instillation of cytostatic or sclerosing agents should be performed to reduce recurrence risk (Class IIa, Level B) 24, 25.
• Intrapericardial agents should be tailored to tumor type:
  
  • Cisplatin for lung‑cancer–related effusions yields 93 % and 83 % recurrence‑free survival at 3 months and 6 months, respectively (Level B).
  • Thiotepa is preferred for breast‑cancer metastases (Level B) 24, 25.
• Tetracycline‑based sclerotherapy achieves control in ~85 % of malignant effusions but is associated with notable adverse effects (fever ≈ 19 %, chest pain ≈ 20 %, atrial arrhythmias ≈ 10 %) (Level C) 24, 25.
• Approximately two‑thirds of cancer patients with pericardial effusion have a non‑malignant etiology (e.g., radiation pericarditis, opportunistic infection); therefore, malignancy must be confirmed before attributing the effusion to cancer (Level C) 24, 25.

Fungal Pericardial Effusion

• Antifungal therapy (fluconazole, ketoconazole, itraconazole, amphotericin B, or liposomal amphotericin B) is indicated for fungal pericarditis (Class IIa, Level B) 24, 25.
• Adjunctive corticosteroids and NSAIDs may be used to support antifungal treatment (Class IIb, Level C) 24, 25.
• Fungal pericarditis occurs predominantly in immunocompromised patients or after exposure in endemic regions (Level C) 24, 25.

Critical Pitfalls in Aortic Dissection‑Related Hemopericardium

• Standard pericardiocentesis must be avoided in aortic dissection with hemopericardium; only minimal, controlled drainage (targeting a systolic blood pressure ≈ 90 mm Hg) may be performed as a bridge to definitive surgical repair (Class I, Level C) 24.